Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.4800
-0.0030 (-0.62%)
Apr 28, 2025, 10:00 AM EDT - Market open

Calidi Biotherapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-22.14-29.22-25.43-10.93-7.94
Depreciation & Amortization
1.541.260.260.160.11
Other Amortization
0.050.430.120.560.08
Loss (Gain) From Sale of Assets
-0.01---
Asset Writedown & Restructuring Costs
---0.17-
Stock-Based Compensation
2.964.814.521.330.97
Other Operating Activities
-0.391.973.74-0.151.01
Change in Accounts Payable
-0.63-6.171.62-0.240.29
Change in Other Net Operating Assets
-1.07-0.071.951.340.65
Operating Cash Flow
-19.69-26.98-13.21-7.77-4.83
Capital Expenditures
-0.02-0.59-0.43-0.21-0.35
Cash Acquisitions
-0.01---
Other Investing Activities
-0.1-0.07-0.01-0.04
Investing Cash Flow
-0.02-0.48-0.49-0.22-0.39
Short-Term Debt Issued
0.83.251.51.50.6
Long-Term Debt Issued
3--0.381.44
Total Debt Issued
3.83.251.51.882.04
Short-Term Debt Repaid
-0.3-1.3-0.04-0.1-0.1
Long-Term Debt Repaid
-1.58-1.05-0.08-0.03-0.06
Total Debt Repaid
-1.88-2.35-0.12-0.13-0.16
Net Debt Issued (Repaid)
1.920.91.381.751.88
Issuance of Common Stock
22.870.280.110.143
Other Financing Activities
2.583.3710.597.93-0
Financing Cash Flow
27.3729.0412.099.814.7
Foreign Exchange Rate Adjustments
-0.01-0.01-0.03-00
Net Cash Flow
7.641.58-1.651.82-0.51
Free Cash Flow
-19.71-27.57-13.64-7.98-5.18
Free Cash Flow Margin
---30315.56%-1777.28%-
Free Cash Flow Per Share
-2.46-16.35-16.04-4.04-3.02
Cash Interest Paid
0.140.40.040.050.02
Cash Income Tax Paid
0.010.010.010.010
Levered Free Cash Flow
-11.21-43.966.7412.15-
Unlevered Free Cash Flow
-10.68-43.726.7211.97-
Change in Net Working Capital
1.5431.08-16.82-16.7-
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q